1-溴-2,4,6-三氟苯 | 2367-76-2

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-2,4,6-三氟苯
• 中文别名: 2-溴-1,3,5-三氟苯2,4,6-三氟溴苯；2,4,6-三氟溴苯；2,4,6-三溴氟苯；2-溴-1,3,5-三氟苯
• 英文名称: 2,4,6-trifluorobromobenzene
• 英文别名: 1-bromo-2,4,6-trifluoro-benzene；2-bromo-1,3,5-trifluorobenzene；2,4,6-trifluoro-1-bromobenzene；1-Bromo-2,4,6-trifluorobenzene
• CAS: 2367-76-2
• 化学式: C₆H₂BrF₃
• mdl: MFCD00000334
• 分子量: 210.981
• InChiKey: PZBSPSOGEVCRQI-UHFFFAOYSA-N

物化性质

• 熔点：
  3.5 °C (lit.)
• 沸点：
  140.5 °C (lit.)
• 密度：
  1.79 g/mL at 25 °C (lit.)
• 闪点：
  137 °F
• 溶解度：
  可溶于氯仿、乙酸乙酯
• 稳定性/保质期：

  避免让氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  3
• 危险品标志：
  Xi
• 安全说明：
  S16,S26,S37/39
• 危险类别码：
  R10,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2903999090
• 危险品运输编号：
  UN 1993 3/PG 3
• 危险类别：
  3
• 包装等级：
  III
• 危险标志：
  GHS02,GHS07
• 危险性描述：
  H226,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  将容器密封后，存放在透气性好的容器中，并储存在阴凉、干燥的地方。

SDS

Name:	1-Bromo-2 4 6-trifluorobenzene 99% Material Safety Data Sheet
Synonym:	None
CAS:	2367-76-2

Section 1 - Chemical Product MSDS Name:1-Bromo-2 4 6-trifluorobenzene 99% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2367-76-2	1-Bromo-2,4,6-trifluorobenzene	99.0	219-125-9

Hazard Symbols: XI
Risk Phrases: 10 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Flammable. Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Vapors may cause dizziness or suffocation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Vapors may form an explosive mixture with air.
Vapors can travel to a source of ignition and flash back. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Will burn if involved in a fire. Use water spray to keep fire-exposed containers cool. Containers may explode in the heat of a fire. Flammable liquid and vapor. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
For small fires, use dry chemical, carbon dioxide, water spray or alcohol-resistant foam. For large fires, use water spray, fog, or alcohol-resistant foam. Use water spray to cool fire-exposed containers. Water may be ineffective. Do NOT use straight streams of water.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Remove all sources of ignition. Use a spark-proof tool. Provide ventilation. A vapor suppressing foam may be used to reduce vapors.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Ground and bond containers when transferring material. Use spark-proof tools and explosion proof equipment. Avoid contact with eyes, skin, and clothing. Empty containers retain product residue, (liquid and/or vapor), and can be dangerous. Keep container tightly closed. Keep away from heat, sparks and flame. Avoid ingestion and inhalation. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose empty containers to heat, sparks or open flames.
Storage:
Keep away from heat, sparks, and flame. Keep away from sources of ignition. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Flammables-area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2367-76-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 140.5 deg C
Freezing/Melting Point: 3.5 deg C
Autoignition Temperature: Not available.
Flash Point: 137 deg F ( 58.33 deg C)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.7900g/cm3
Molecular Formula: C6H2BrF3
Molecular Weight: 210.99

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2367-76-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Bromo-2,4,6-trifluorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3
UN Number: 1993
Packing Group: III
IMO
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3
UN Number: 1993
Packing Group: III
RID/ADR
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3
UN Number: 1993
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 10 Flammable.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 9 Keep container in a well-ventilated place.
S 16 Keep away from sources of ignition - No
smoking.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 33 Take precautionary measures against static
discharges.
S 37 Wear suitable gloves.
S 37/39 Wear suitable gloves and eye/face
protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2367-76-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2367-76-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2367-76-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：沸点为140.5℃，熔点为3.5℃，闪点大于110℃，折光率为1.4850，比重为1.790。

用途：用于医药、农药及液晶材料中间体。

反应信息

• 作为反应物：
  描述：

  1-溴-2,4,6-三氟苯 在 正丁基锂 、 硼酸三甲酯 、 盐酸 作用下， 以 乙醚 、 正己烷 为溶剂， 生成 2,4,6-三氟苯硼酸
  参考文献：
  名称：

  (Fluoroorgano)fluoroboranes and -fluoroborates I: synthesis and spectroscopic characterization of potassium fluoroaryltrifluoroborates and fluoroaryldifluoroboranes

  摘要：

  A convenient preparation of K[ArBF3] (Ar= 2-C6H4F, 3-C6H4F, 4-C6H4F, 2,6-C6H3F2, 3,5-C6H3F2, 2,4,6-C6H2F3, 3,4,5-C6H2F3, 2,3,4,5-C6HF4 and C6F5) is offered and the IR and multinuclear NMR spectra of these salts are reported. Treatment of the trifluoroborate salts with BF3 in chlorocarbon solvents provides an easy synthetic route to the corresponding aryldifluoroboranes ArBF2. The multinuclear NMR spectra of ArBF2 are presented. The electron substituent effect of the [-BF3](-)-group shows this substituent as one of the strongest sigma-electron donors, while its pi-electron influence is negligible (sigma(I) = - 0.32, sigma(R) = - 0.07). (C) 2000 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0022-328x(99)00690-7
• 作为产物：
  描述：

  2,4-二氟乙酰苯胺 在 nitrosylsulfuric acid 、 磷酸 、 硫酸 、 溴 、 硝酸 、 铁粉 、 氯化铵 作用下， 生成 1-溴-2,4,6-三氟苯
  参考文献：
  名称：

  Aromatic Fluorine Compounds. V. 1,3,5-Trifluorobenzene¹

  摘要：

  DOI：

  10.1021/ja01145a055
• 作为试剂：
  描述：

  盐酸胍 、 1-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-3,3-bis(methylsulfanyl)-2-propenone 在 1-溴-2,4,6-三氟苯 、 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 2.0h， 生成 4-(5-chloro-1H,3H-benzo[de]isochromen-6-yl)-6-methylsulfanyl-pyrimidin-2-ylamine
  参考文献：
  名称：

  HSP90 INHIBITOR

  摘要：

  公开号：

  EP2036895B1

文献信息

• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：PROPELLON THERAPEUTICS INC

  公开号：WO2019046944A1

  公开（公告）日：2019-03-14

  The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：(I) 包括这些化合物的组合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、紊乱或状况的药物。
• [EN] DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY<br/>[FR] ANTAGONISTES DU RÉCEPTEUR D3 DE LA DOPAMINE AYANT UN FRAGMENT BICYCLO
  申请人：INDIVIOR UK LTD

  公开号：WO2017021920A1

  公开（公告）日：2017-02-09

  The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

  该披露提供了具有化学式（I）的化合物，其中取代基如本文所定义。这些化合物可用于调节多巴胺D3受体，并用于治疗与之相关的疾病，如成瘾、药物依赖和精神疾病。
• Process for preparation of benzo[f]quinolinones
  申请人：Eli Lilly and Company

  公开号：US05578724A1

  公开（公告）日：1996-11-26

  A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase and their preparation is disclosed.

  一系列苯醌啉-3-酮类药物在治疗由I型和II型5α-还原酶引起的疾病方面具有有效性，并且其制备方法已被披露。
• [EN] PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS PHÉNOXY-PYRIDYL-PYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：GENENTECH INC

  公开号：WO2020056089A1

  公开（公告）日：2020-03-19

  Described herein are phenoxy-pyridyl -pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了具有肌醇需要酶1（IRE1）调节活性或功能的苯氧基吡啶基嘧啶化合物，其具有Formula I结构或立体异构体、互变异构体或其药用可接受的盐，并具有所述的取代基和结构特征。还描述了包括Formula I化合物的药物组合物和药物，以及使用这种IRE1调节剂的方法，单独或与其他治疗剂联合使用，用于治疗通过雌激素受体介导或依赖的疾病或症状。
• 4-Aryl piperidines
  申请人：Marzabadi R. Mohammad

  公开号：US20050154020A1

  公开（公告）日：2005-07-14

  This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  本发明涉及4-芳基哌啶及其相关杂环化合物，这些化合物是对黑素集中激素-1（MCH1）受体的选择性拮抗剂。本发明提供了一种药物组合物，包括治疗有效量的本发明化合物和药用可接受的载体。本发明还提供了一种通过结合治疗有效量的本发明化合物和药用可接受的载体而制成的药物组合物。本发明进一步提供了一种制备药物组合物的方法，包括结合治疗有效量的本发明化合物和药用可接受的载体。本发明还提供了一种减少主体体质量的方法，包括向主体施用有效减少主体体质量的本发明化合物的量。本发明还进一步提供了一种治疗患有抑郁和/或焦虑的主体的方法，包括向主体施用有效治疗主体的抑郁和/或焦虑的本发明化合物的量。

表征谱图